These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 34716040)
1. Scalable production and immunogenicity of a cholera conjugate vaccine. Jeon S; Kelly M; Yun J; Lee B; Park M; Whang Y; Lee C; Halvorsen YD; Verma S; Charles RC; Harris JB; Calderwood SB; Leung DT; Bhuiyan TR; Qadri F; Kamruzzaman M; Cho S; Vann WF; Xu P; Kováč P; Ganapathy R; Lynch J; Ryan ET Vaccine; 2021 Nov; 39(47):6936-6946. PubMed ID: 34716040 [TBL] [Abstract][Full Text] [Related]
2. A Cholera Conjugate Vaccine Containing O-specific Polysaccharide (OSP) of V. cholerae O1 Inaba and Recombinant Fragment of Tetanus Toxin Heavy Chain (OSP:rTTHc) Induces Serum, Memory and Lamina Proprial Responses against OSP and Is Protective in Mice. Sayeed MA; Bufano MK; Xu P; Eckhoff G; Charles RC; Alam MM; Sultana T; Rashu MR; Berger A; Gonzalez-Escobedo G; Mandlik A; Bhuiyan TR; Leung DT; LaRocque RC; Harris JB; Calderwood SB; Qadri F; Vann WF; Kováč P; Ryan ET PLoS Negl Trop Dis; 2015; 9(7):e0003881. PubMed ID: 26154421 [TBL] [Abstract][Full Text] [Related]
3. Vaccination of Rabbits with a Cholera Conjugate Vaccine Comprising O-Specific Polysaccharide and a Recombinant Fragment of Tetanus Toxin Heavy Chain Induces Protective Immune Responses against Vibrio cholerae O1. Kelly M; Jeon S; Yun J; Lee B; Park M; Whang Y; Lee C; Charles RC; Bhuiyan TR; Qadri F; Kamruzzaman M; Cho S; Vann WF; Xu P; Kováč P; Ganapathy R; Lynch J; Ryan ET Am J Trop Med Hyg; 2023 Nov; 109(5):1122-1128. PubMed ID: 37783453 [TBL] [Abstract][Full Text] [Related]
4. Defining Polysaccharide-Specific Antibody Targets against Vibrio cholerae O139 in Humans following O139 Cholera and following Vaccination with a Commercial Bivalent Oral Cholera Vaccine, and Evaluation of Conjugate Vaccines Targeting O139. Kamruzzaman M; Kelly M; Charles RC; Harris JB; Calderwood SB; Akter A; Biswas R; Kaisar MH; Bhuiyan TR; Ivers LC; Ternier R; Jerome JG; Pfister HB; Lu X; Soliman SE; Ruttens B; Saksena R; Mečárová J; Čížová A; Qadri F; Bystrický S; Kováč P; Xu P; Ryan ET mSphere; 2021 Aug; 6(4):e0011421. PubMed ID: 34232076 [TBL] [Abstract][Full Text] [Related]
5. Induction of systemic, mucosal and memory antibody responses targeting Vibrio cholerae O1 O-specific polysaccharide (OSP) in adults following oral vaccination with an oral killed whole cell cholera vaccine in Bangladesh. Akter A; Dash P; Aktar A; Jahan SR; Afrin S; Basher SR; Hakim A; Lisa AK; Chowdhury F; Khan AI; Xu P; Charles RC; Kelly M; Kováč P; Harris JB; Bhuiyan TR; Calderwood SB; Ryan ET; Qadri F PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007634. PubMed ID: 31369553 [TBL] [Abstract][Full Text] [Related]
6. Comparison of O-specific polysaccharide responses in patients following infection with Kaisar MH; Kelly M; Kamruzzaman M; Bhuiyan TR; Chowdhury F; Khan AI; LaRocque RC; Calderwood SB; Harris JB; Charles RC; Čížová A; Mečárová J; Korcová J; Bystrický S; Kováč P; Xu P; Qadri F; Ryan ET mSphere; 2023 Oct; 8(5):e0025523. PubMed ID: 37646517 [TBL] [Abstract][Full Text] [Related]
7. Evaluation in mice of a conjugate vaccine for cholera made from Vibrio cholerae O1 (Ogawa) O-specific polysaccharide. Alam MM; Bufano MK; Xu P; Kalsy A; Yu Y; Freeman YW; Sultana T; Rashu MR; Desai I; Eckhoff G; Leung DT; Charles RC; LaRocque RC; Harris JB; Clements JD; Calderwood SB; Qadri F; Vann WF; Kováč P; Ryan ET PLoS Negl Trop Dis; 2014 Feb; 8(2):e2683. PubMed ID: 24516685 [TBL] [Abstract][Full Text] [Related]
8. Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers. Islam K; Hossain M; Kelly M; Mayo Smith LM; Charles RC; Bhuiyan TR; Kováč P; Xu P; LaRocque RC; Calderwood SB; Simon JK; Chen WH; Haney D; Lock M; Lyon CE; Kirkpatrick BD; Cohen M; Levine MM; Gurwith M; Harris JB; Qadri F; Ryan ET PLoS Negl Trop Dis; 2018 Apr; 12(4):e0006376. PubMed ID: 29624592 [TBL] [Abstract][Full Text] [Related]
9. Cholera toxin and O-specific polysaccharide immune responses after oral cholera vaccination with Dukoral in different age groups of Bangladeshi participants. Dash P; Hakim A; Akter A; Banna HA; Kaisar MH; Aktar A; Jahan SR; Ferdous J; Basher SR; Kamruzzaman M; Chowdhury F; Akter A; Tauheed I; Weil AA; Charles RC; Calderwood SB; Ryan ET; LaRocque RC; Harris JB; Bhuiyan TR; Qadri F mSphere; 2024 Mar; 9(3):e0056523. PubMed ID: 38391226 [TBL] [Abstract][Full Text] [Related]
10. Parenteral Vaccination with a Cholera Conjugate Vaccine Boosts Vibriocidal and Anti-OSP Responses in Mice Previously Immunized with an Oral Cholera Vaccine. Akter A; Kelly M; Charles RC; Harris JB; Calderwood SB; Bhuiyan TR; Biswas R; Xu P; Kováč P; Qadri F; Ryan ET Am J Trop Med Hyg; 2021 Apr; 104(6):2024-2030. PubMed ID: 33872211 [TBL] [Abstract][Full Text] [Related]
11. Transcutaneous immunization with a Vibrio cholerae O1 Ogawa synthetic hexasaccharide conjugate following oral whole-cell cholera vaccination boosts vibriocidal responses and induces protective immunity in mice. Tarique AA; Kalsy A; Arifuzzaman M; Rollins SM; Charles RC; Leung DT; Harris JB; Larocque RC; Sheikh A; Bhuiyan MS; Saksena R; Clements JD; Calderwood SB; Qadri F; Kovác P; Ryan ET Clin Vaccine Immunol; 2012 Apr; 19(4):594-602. PubMed ID: 22357651 [TBL] [Abstract][Full Text] [Related]
12. Comparison of immune responses to the O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 in Bangladeshi adult patients with cholera. Johnson RA; Uddin T; Aktar A; Mohasin M; Alam MM; Chowdhury F; Harris JB; LaRocque RC; Bufano MK; Yu Y; Wu-Freeman Y; Leung DT; Sarracino D; Krastins B; Charles RC; Xu P; Kovác P; Calderwood SB; Qadri F; Ryan ET Clin Vaccine Immunol; 2012 Nov; 19(11):1712-21. PubMed ID: 22993410 [TBL] [Abstract][Full Text] [Related]
13. Immune responses to O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 Ogawa in adult Bangladeshi recipients of an oral killed cholera vaccine and comparison to responses in patients with cholera. Uddin T; Aktar A; Xu P; Johnson RA; Rahman MA; Leung DT; Afrin S; Akter A; Alam MM; Rahman A; Chowdhury F; Khan AI; Bhuiyan TR; Bufano MK; Rashu R; Yu Y; Wu-Freeman Y; Harris JB; LaRocque RC; Charles RC; Kováč P; Calderwood SB; Ryan ET; Qadri F Am J Trop Med Hyg; 2014 May; 90(5):873-81. PubMed ID: 24686738 [TBL] [Abstract][Full Text] [Related]
14. Virus-like Particle Display of Rashidijahanabad Z; Kelly M; Kamruzzaman M; Qadri F; Bhuiyan TR; McFall-Boegeman H; Wu D; Piszczek G; Xu P; Ryan ET; Huang X ACS Infect Dis; 2022 Mar; 8(3):574-583. PubMed ID: 35170309 [No Abstract] [Full Text] [Related]
15. Plasma and memory B cell responses targeting O-specific polysaccharide (OSP) are associated with protection against Vibrio cholerae O1 infection among household contacts of cholera patients in Bangladesh. Aktar A; Rahman MA; Afrin S; Akter A; Uddin T; Yasmin T; Sami MIN; Dash P; Jahan SR; Chowdhury F; Khan AI; LaRocque RC; Charles RC; Bhuiyan TR; Mandlik A; Kelly M; Kováč P; Xu P; Calderwood SB; Harris JB; Qadri F; Ryan ET PLoS Negl Trop Dis; 2018 Apr; 12(4):e0006399. PubMed ID: 29684006 [TBL] [Abstract][Full Text] [Related]
16. Immune responses to the O-specific polysaccharide antigen in children who received a killed oral cholera vaccine compared to responses following natural cholera infection in Bangladesh. Leung DT; Uddin T; Xu P; Aktar A; Johnson RA; Rahman MA; Alam MM; Bufano MK; Eckhoff G; Wu-Freeman Y; Yu Y; Sultana T; Khanam F; Saha A; Chowdhury F; Khan AI; Charles RC; Larocque RC; Harris JB; Calderwood SB; Kovác P; Qadri F; Ryan ET Clin Vaccine Immunol; 2013 Jun; 20(6):780-8. PubMed ID: 23515016 [TBL] [Abstract][Full Text] [Related]
17. O-Specific Polysaccharide-Specific Memory B Cell Responses in Young Children, Older Children, and Adults Infected with Vibrio cholerae O1 Ogawa in Bangladesh. Aktar A; Rahman MA; Afrin S; Faruk MO; Uddin T; Akter A; Sami MIN; Yasmin T; Chowdhury F; Khan AI; Leung DT; LaRocque RC; Charles RC; Bhuiyan TR; Mandlik A; Kelly M; Kováč P; Xu P; Calderwood SB; Harris JB; Qadri F; Ryan ET Clin Vaccine Immunol; 2016 May; 23(5):427-435. PubMed ID: 27009211 [TBL] [Abstract][Full Text] [Related]
18. Immune responses to O-specific polysaccharide (OSP) in North American adults infected with Vibrio cholerae O1 Inaba. Hossain M; Islam K; Kelly M; Mayo Smith LM; Charles RC; Weil AA; Bhuiyan TR; Kováč P; Xu P; Calderwood SB; Simon JK; Chen WH; Lock M; Lyon CE; Kirkpatrick BD; Cohen M; Levine MM; Gurwith M; Leung DT; Azman AS; Harris JB; Qadri F; Ryan ET PLoS Negl Trop Dis; 2019 Nov; 13(11):e0007874. PubMed ID: 31743334 [TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age. Saha A; Chowdhury MI; Khanam F; Bhuiyan MS; Chowdhury F; Khan AI; Khan IA; Clemens J; Ali M; Cravioto A; Qadri F Vaccine; 2011 Oct; 29(46):8285-92. PubMed ID: 21907255 [TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of a killed bivalent (O1 and O139) whole cell oral cholera vaccine, Shanchol, in Haiti. Charles RC; Hilaire IJ; Mayo-Smith LM; Teng JE; Jerome JG; Franke MF; Saha A; Yu Y; Kováč P; Calderwood SB; Ryan ET; LaRocque RC; Almazor CP; Qadri F; Ivers LC; Harris JB PLoS Negl Trop Dis; 2014 May; 8(5):e2828. PubMed ID: 24786645 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]